OncLive® On Air

In this episode, produced in coordination with Oncology Nursing News®, Beth Faiman, PhD, MSN, APN-BC, AOCN, FAAN, FAPO, and Sikander Ailawadhi, MD, discussed how on-body subcutaneous administration methods are affecting multiple myeloma management and how these administrations could be a key focus of future health care initiatives. Dr Faiman is an adult nurse practitioner in the Department of Hematology/Oncology at the Cleveland Clinic and a clinical member of the Cancer Prevention, Control and Population Research Program at Case Comprehensive Cancer Center in Ohio. Dr Ailawadhi is a consultant in the Division of Hematology/Oncology in the Department of Internal Medicine, a consultant in the Department of Cancer Biology, and a professor of medicine at Mayo Clinic in Rochester, Minnesota.
In the second episode of a 3-part series, Drs Faiman and Ailawadhi explained how on-body administration of isatuximab-irfc (Sarclisa Escena) for subcutaneous injection is setting the stage for future patient-centric treatment methods, and the pair discussed experiences with this method.
In the first episode, Drs Faiman and Ailawadhi detailed the transition to subcutaneous administration of anti-CD38 monoclonal antibodies in multiple myeloma management.

In today’s episode, we spoke with Vincent Chung, MD, about the development of atebimetinib (IMM-1-104) in metastatic pancreatic cancer. Dr Chung is a professor in the Department of Medical Oncology & Therapeutics Research at City of Hope in Duarte, California.
In our exclusive interview, Dr Chung discussed MEK inhibition as a logical target in metastatic pancreatic cancer, the unique mechanism of action of atebimetinib that contributes to its improved tolerability relative to earlier-generation MEK inhibitors, key safety and efficacy findings from a phase 2a trial (NCT05585320) combining atebimetinib with modified gemcitabine/nab-paclitaxel (Abraxane) in patients with advanced or metastatic disease, and how the outcomes of the ongoing phase 3 MAPkeeper-301 trial may affect the treatment paradigm going forward.

In today’s episode, we welcomed Ruben Mesa, MD, FACP, who outlined the significance of the August 2026 FDA approval of ropeginterferon alfa-2b-njft (Besremi) for the treatment of adult patients with essential thrombocythemia. Dr Mesa is senior vice president of Atrium Health and president and executive director of the Atrium Health Wake Forest Baptist Comprehensive Cancer Center in Charlotte, North Carolina.
In the exclusive interview, Dr Mesa discussed what the FDA approval of ropeginterferon alfa-2b means for the essential thrombocythemia treatment paradigm, detailed the key efficacy and safety findings from the phase 3 SURPASS-ET trial (NCT04285086) that supported the approval, and looked ahead to other research that could continue to affect this space.

In today’s episode, we spoke with Kim A. Reiss Binder, MD, about the August 2026 FDA approval of daraxonrasib (Rasonque) for the treatment of adult patients with metastatic pancreatic adenocarcinoma who have received at least 1 prior systemic therapy or are not candidates for multi-agent systemic therapy. Dr Reiss Binder is the assistant program director of the Hematology/Oncology Fellowship Program and an associate professor of medicine (hematology-oncology) at the Hospital of the University of Pennsylvania in Philadelphia.
In our exclusive interview, Dr Binder discussed the significance of this approval, key efficacy data from the pivotal phase 3 RASolute 302 trial (NCT06625320), and the importance of continuing to build off of treatment advances to drive clinical research and improve patient outcomes in this field.

In this episode, we spoke with Arndt Vogel, MD, a faculty member at the University of Toronto Institute of Medical Science, a scientist at the Toronto General Hospital Research Institute, and a medical oncologist at the UHN–Princess Margaret Cancer Centre in Canada.
In our exclusive interview, Dr Vogel highlighted the rationale and growing evidence for sequential FGFR inhibition in FGFR2 fusion–positive cholangiocarcinoma, explaining that on-target resistance mutations and the differing binding properties of agents like pemigatinib (Pemazyre), futibatinib (Lytgobi), and the more selective tinengotinib (TT-00420) support using these drugs in sequence, although he emphasized that treatment decisions remain biomarker-informed rather than biomarker-guided. He also stressed the importance of early, RNA-based next-generation sequencing, the emerging role of circulating tumor DNA in capturing polyclonal resistance, and his anticipation of forthcoming phase 3 tinengotinib data.